Entyvio drives Takeda's Q1 revenue growth: 6 things to know

Takeda released its first quarter 2018 revenue numbers.

Here are six details to know:

1. Takeda's underlying revenue growth in gastroenterology, oncology, neuroscience and emerging market divisions grew 6.4 percent.

2. The key products contributing to revenue growth were Entyvio and Ninlaro.

3. Takeda's U.S.-based underlying revenue increased 14.1 percent.

4. "Takeda's strong business momentum continues into 2018 as we make solid progress against our key priorities to grow the portfolio, strengthen the pipeline, and boost profitability,' said Costa Saroukos, Takeda's CFO. "This margin growth was predominantly driven by Opex discipline, which is indicative of how the Global Opex Initiative is now fully integrated into how we work through KPIs, objectives, budgets and systems."

5. Takeda reported 449.8 billion yen ($4.028 billion) in revenue, up .4 percent from the first quarter of 2017.

6. Takeda's operating profits declined 49.3 percent year over year. The loss was attributed to declining sales of Velcade and was partially offset by the sale of Wake Pure Chemical. Velcade lost market exclusivity for Velcade.

More articles on GI and endoscopy:
Exact Sciences missed Q2 expectations tanks stock — 7 insights
6 quotes from Exact Sciences CEO Kevin Conroy on Q2 results
GI leader to know: Dr. Mary Atia of Arizona Digestive Health

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Top 40 Articles from the Past 6 Months